A first-in-class bifunctional antibody targeting CD20 and CD37 remodels the immune microenvironment in relapsed or refractory B-cell malignancies - PubMed
4 hours ago
- #Bifunctional Antibody
- #B-Cell Lymphoma
- #Immune Microenvironment
- PSB202 is a first-in-class bifunctional antibody targeting CD20 and CD37 for treating relapsed or refractory B-cell malignancies.
- In a phase Ia trial (NCT05003141), escalating doses (12-300 mg) were given to 15 heavily pretreated patients; MTD was not reached.
- Safety profile was manageable, with grade ≥3 neutropenia and leukopenia in 60% of patients and a 30% overall response rate.
- PSB202 achieved sustained B-cell depletion and induced IFN-γ release without cytokine release syndrome, remodeling the immune microenvironment.
- The findings support PSB202 as a novel off-the-shelf therapeutic alternative that may mitigate CD3-related toxicity while promoting immune activation.